CDTX Profile
Cidara Therapeutics, Inc., based in San Diego, California, is a biotechnology company specializing in the discovery, development, and commercialization of innovative anti-infectives with a focus on long-acting therapies. Founded in 2012 and previously known as K2 Therapeutics, Inc., the company aims to address significant unmet needs in the treatment and prevention of infectious diseases and oncology. Its research and development efforts are primarily concentrated on novel approaches to combating severe infections and enhancing patient outcomes.
The company's flagship product candidate is rezafungin acetate, a groundbreaking molecule within the echinocandin class of antifungals. Rezafungin is designed to offer prolonged protection against invasive fungal infections such as candidemia and invasive candidiasis, which are known for their high mortality rates and challenging treatment regimens. Rezafungin is currently undergoing clinical trials to demonstrate its efficacy and safety in treating and preventing these serious infections.
In addition to rezafungin, Cidara Therapeutics is advancing its proprietary Cloudbreak platform, which is dedicated to developing novel conjugates for the prevention and treatment of a range of viral infections. This includes efforts to combat influenza, respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and the SARS-CoV-2 strains responsible for COVID-19. The Cloudbreak platform represents a significant innovation in therapeutic development, leveraging advanced science to create targeted treatments for these global health challenges.
Cidara's commitment to advancing medical science through its pioneering anti-infective therapies and platforms underscores its role in addressing critical health issues. By focusing on long-acting solutions and leveraging cutting-edge technology, Cidara Therapeutics is positioned to make a substantial impact on the management of infectious diseases and the broader field of oncology.
|
